<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03566472</url>
  </required_header>
  <id_info>
    <org_study_id>KY20170904-05</org_study_id>
    <nct_id>NCT03566472</nct_id>
  </id_info>
  <brief_title>The Blood Glucose Control in Patients With Type 2 Diabetes Treated With Glargine</brief_title>
  <official_title>The Current Situation and Influence Factors of Blood Glucose Control in Patients With Type 2 Diabetes Treated With Glargine in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glargine is commonly used in insulin supplemental therapy in patients with type 2&#xD;
      diabetes(T2D) at present. This study aims to investigate the current status of blood glucose&#xD;
      control in patients with T2D treated with glargine. Glycated hemoglobin(HbA1c) will be tested&#xD;
      in these patients to assess the blood glucose control and Continuous Glucose Monitoring&#xD;
      System (CGMS) will be used to investigate the glucose variability. Islet function, duration&#xD;
      of diabetes, complications, exercise, insulin dose, oral medication regimen and insulin&#xD;
      antibodies will be recorded in detail. This study will analysis the association between these&#xD;
      clinical characteristics and blood glucose control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 12, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Day 1</time_frame>
    <description>Blood glycated hemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MBG</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>24 h mean blood glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MAGE</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>24 h mean amplitude of glycemic excursions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SDBG</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>the standard deviation of the MBG</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type2 Diabetes</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Continuous Glucose Monitoring System</intervention_name>
    <description>Continuous Glucose Monitoring System for 72 hours</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese outpatients with type 2 diabetes in Nanjing First Hospital who meet the the&#xD;
        eligibility criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with T2DM, which was defined bypublished Criteria of World Health&#xD;
             Organization in 1999;&#xD;
&#xD;
          2. Patients were using glargine with or without oral hypoglycemic drugs and having a&#xD;
             stable dose of glargine for more than 2 month would be recruited into this study;&#xD;
&#xD;
          3. Patients had relatively constant diet and exercise in 2 month before the study;&#xD;
&#xD;
          4. Fasting blood glucose was between 6.1 and 16mmolL, and postprandial (or random) blood&#xD;
             glucose &lt;22.2mmol/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe cardiovascular diseases, such as stroke, transient ischemic&#xD;
             attack, myocardial infarction, unstable angina, coronary artery bypass grafting,&#xD;
             percutaneous coronary intervention, and heart failure;&#xD;
&#xD;
          2. Patients with severe infectious diseases;&#xD;
&#xD;
          3. Patients with acute complications of diabetes on admission, such as diabetic&#xD;
             ketoacidosis, diabetic hyperosmolar nonketotic coma, and lactic acidosis;&#xD;
&#xD;
          4. Patients with history of psychiatric disorders and were unsuitable to use CGMS;&#xD;
&#xD;
          5. Any other situations that made patients unsuitable to participate in the study, such&#xD;
             as alcoholism and drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ma Jianhua</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ma Jianhua</last_name>
    <phone>8625-52887092</phone>
    <email>majianhua196503@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanjing First Hostital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Ma, Doctor</last_name>
      <phone>+8618951670116</phone>
      <email>majianhua196503@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2018</study_first_posted>
  <last_update_submitted>June 9, 2019</last_update_submitted>
  <last_update_submitted_qc>June 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

